Luke Carter-Brzezinski - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Luke Carter-Brzezinski

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

British Journal of Hospital Medicine (London, England : 2005)|August 25, 2021

D-dimers: a most misunderstood testLuke Carter-Brzezinski, Scott Houston, Jecko Thachil

Blood Reviews|November 24, 2020

Management of venous thromboembolism in athletesDawn Swan, Luke Carter-Brzezinski, Jecko Thachil

Blood|November 14, 2023

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

British Journal of Hospital Medicine (London, England : 2005)|August 25, 2021

D-dimers: a most misunderstood testLuke Carter-Brzezinski, Scott Houston, Jecko Thachil

Blood Reviews|November 24, 2020

Management of venous thromboembolism in athletesDawn Swan, Luke Carter-Brzezinski, Jecko Thachil

Blood|November 14, 2023

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.

Pageof 1